Figure 2.

Sublingual immunotherapy reduces pro‐allergic Th2 cells. Percentages of CD27⁻CRTh2⁺CCR4⁺ among CD3⁺CD4⁺CD45RA⁻ T cells in PBMC collected before and after 4 and 16 wk of treatment with rMal d 1 (n = 9) and placebo (n = 8) were determined by flow cytometry. The percentage before treatment was individually normalized to 100. (*P < 0.05, **P < 0.01, repeated measures one‐way ANOVA with Tukey post hoc test)